

# Roberto Ferrara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/690625/publications.pdf>

Version: 2024-02-01

67  
papers

4,669  
citations

218592

26  
h-index

114418

63  
g-index

67  
all docs

67  
docs citations

67  
times ranked

6726  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	0.8	747
2	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	3.4	599
3	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 1543.	3.4	567
4	Hyperprogressive disease: recognizing a novel pattern to improve patient management. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 748-762.	12.5	304
5	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018, 88, 38-47.	1.3	248
6	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin remodelling genes as major players and a prognostic role for <i>TERT</i> , <i>RB1</i> and <i>MEN1</i> and <i>KMT2D</i> . <i>Journal of Pathology</i> , 2017, 241, 488-500.	2.1	179
7	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1244-1254.	0.5	178
8	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 106, 144-159.	1.3	164
9	Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 27-45.	0.5	156
10	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019, 4, e000457.	2.0	151
11	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. <i>Cancer Treatment Reviews</i> , 2017, 60, 60-68.	3.4	125
12	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	3.4	124
13	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 492-503.	3.2	76
14	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1039.	3.4	70
15	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. <i>European Journal of Cancer</i> , 2019, 109, 28-35.	1.3	69
16	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
17	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. <i>Oncologist</i> , 2020, 25, 94-98.	1.9	58
18	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	1.7	57

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 38-42.	0.9	44
20	Progress in the Management of Advanced Thoracic Malignancies in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 301-322.	0.5	43
21	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 116, 182-189.	1.3	36
22	Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2019, 108, 88-96.	1.3	36
23	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020, 12, 2827.	1.7	35
24	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	1.5	35
25	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 621-631.	1.0	35
26	Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 328-331.	0.5	31
27	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 12, CD013257.	1.5	30
28	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. <i>Cancers</i> , 2020, 12, 3625.	1.7	27
29	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2253-2266.	0.9	26
30	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy. <i>JCO Precision Oncology</i> , 2020, 4, 829-840.	1.5	25
31	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 122, 340-347.	2.9	24
32	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	0.9	23
33	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers Letter. <i>Clinical Cancer Research</i> , 2019, 25, 3468-3468.	3.2	22
34	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1113-1129.	0.9	20
35	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 41.	1.8	20
36	The development of PARP as a successful target for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 161-175.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. Journal of Clinical Oncology, 2018, 36, 9003-9003.	0.8	16
38	Afatinib in patients with metastatic <i>HER2</i> -mutant lung cancers: An international multicenter study.. Journal of Clinical Oncology, 2017, 35, 9071-9071.	0.8	14
39	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy. Cancers, 2022, 14, 435.	1.7	14
40	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. Expert Opinion on Biological Therapy, 2015, 15, 1359-1370.	1.4	13
41	Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. Oncotarget, 2018, 9, 1906-1914.	0.8	13
42	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. Cellular Immunology, 2021, 362, 104301.	1.4	12
43	Atypical patterns of response and progression in the era of immunotherapy combinations. Future Oncology, 2020, 16, 1707-1713.	1.1	11
44	Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a New Frontier?. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 307-313.	0.9	11
45	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respiratory Research, 2016, 17, 105.	1.4	10
46	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. Cancers, 2021, 13, 1300.	1.7	10
47	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunology, Immunotherapy, 2021, 70, 2429-2438.	2.0	10
48	Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).. Journal of Clinical Oncology, 2019, 37, 9107-9107.	0.8	10
49	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. Translational Lung Cancer Research, 2020, 9, 617-628.	1.3	8
50	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncology, 2019, 15, 2743-2757.	1.1	7
51	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1143-1161.	1.9	6
52	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2019, 20, e652-e660.	1.1	6
53	Hyperprogression—Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer—In Reply. JAMA Oncology, 2019, 5, 744.	3.4	6
54	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clinical Lung Cancer, 2020, 21, e337-e348.	1.1	6

#	ARTICLE	IF	CITATIONS
55	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. <i>Current Oncology</i> , 2022, 29, 3499-3518.	0.9	6
56	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103299.	2.0	5
57	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2019, , .	1.5	3
58	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. <i>Precision Cancer Medicine</i> , 2019, 2, 35-35.	1.8	3
59	Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9089-9089.	0.8	3
60	Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. <i>Future Oncology</i> , 2022, 18, 2593-2604.	1.1	3
61	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. <i>Future Science OA</i> , 2015, 1, FSO29.	0.9	2
62	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. <i>Translational Lung Cancer Research</i> , 2021, 10, 2955-2969.	1.3	2
63	Is hyperprogressive disease a specific phenomenon of immunotherapy?. <i>Exploration of Targeted Anti-tumor Therapy</i> , 2020, 1, .	0.5	1
64	Prognostic value of <i>ALK</i> gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19059-e19059.	0.8	0
65	Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that?. <i>Translational Cancer Research</i> , 2016, 5, S462-S466.	0.4	0
66	Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9066-9066.	0.8	0
67	Facing the First-line in Metastatic Non-small-cell Lung Cancer “ Immunotherapy and Chemotherapy. <i>European Oncology and Haematology</i> , 2020, 16, 39.	0.0	0